 |
Цитата: |
 |
|
|
 |
Сообщение от Law-N-Order |
 |
|
|
|
|
|
|
|
|
Сай, у меня другая мысль уже давно: чтобы поставить на место оппонентов, Иваницкому, Шнолю и Маевскому хорошо бы влить самим перфторан добровольно без острой необходимости, показав тем самым, что вот он какой полезный и безвредный - желательно с трансляцией из палаты. :-)
|
|
 |
|
 |
|
Хорошая мысль, а вы из своих рядов выделите человека, чтоб доказал обратное на себе. Пострадайте за науку: отравите себя перфтораном!
Не знаю, специально или нет, но вы запустили песенку про белого бычка по кругу. Мне кажется, что Нитрус готов выложить 1-ый пост заново.
Выкладываю три статьи из пабмеда, правда, две из них экспериментальные из Польши и РФ. Посмотрите также один доклад.
1. Artif Cells Blood Substit Immobil Biotechnol. 2008;36(6):525-34.
Impact of oxygenation of bioartificial liver using perfluorocarbon emulsion perftoran on metabolism of human hepatoma C3A cells.
Kinasiewicz A, Smietanka A, Gajkowska B, Werynski A.
Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Trojdena 4, Warsaw, Poland.
kinas@ibib.waw.pl
Abstract
One of the most important challenges in bioartificial liver designed for patients suffering from acute liver failure is oxygenation of cells within the bioreactor. The aim of this study was to evaluate the impact of oxygenation of bioartificial liver using perfluorocarbon (PFC) emulsion on the metabolic activity of hepatic cells in vitro. Mineral fibers coated with collagen type I were used as scaffolds for hepatic cells. Significantly higher total protein synthesis by hepatic C3A cells cultured in the bioreactor for 24 hours, in the group treated with medium supplemented with PFC emulsion, was observed in comparison with medium without PFC. Albumin production increased in the group treated with PFC after 1 hour of perfusion and was continuously, statistically, significantly higher during perfusion then the control group. In conclusion, the use of oxygen carriers, such as the PFC emulsion, can significantly improve synthetic performance of the bioreactor. Mineral fibers coated with extracellular proteins may serve as support for hepatic cells in the bioreactor.
2. Transplant Proc. 2008 May;40(4):1027-8.
The use of oxygenated perfluorocarbonic emulsion for initial in situ kidney perfusion.
Reznik ON, Bagnenko SF, Loginov IV, Iljina VA, Ananyev AN, Moysyuk YG.
St Petersburg State Research Institute for Emergency named after I.I. Dzhanelidze, Saint Petersburg, Russia.
onreznik@yahoo.com
Abstract
Protection of grafts from ischemia-reperfusion injury (IRI) remains an important problem, especially in uncontrolled donors. This study was performed to define the effect of oxygenated perfluorocarbonic emulsion for initial in situ conservation. One hundred and seventeen kidney grafts were procured from 2003 until 2006 from sixty one DCDs of Maastricht II and IV category. Control group donors (HTK group, n = 31) were operated using the traditional rapid laparotomy. The study group donors (Perftoran group, n = 30) had femoral access obtained in the ICU with initial perfusion by perfluorocarbonic PFG emulsion. The recipients were divided according to the type of the initial perfusion of the kidneys into a control group (n = 59) whose kidneys were initially perfused using HTK solution, and a study group (n = 58), who received kidneys preserved with initial perfusion in situ using oxygenated Perftoran. The rate of delayed graft function was significantly (up to 30
higher among the control group. In the study group, the rate of immediate function was twice as high as that in the control group. By postoperative day 21, the level of serum creatinine in the study group decreased twice that of the control group. Initial perfusion with oxygenated perfluorocarbonic emulsion in situ may minimize a IRI of DCD kidneys.
3. J Craniomaxillofac Surg. 2008 Apr;36(3):161-72. Epub 2008 Mar 19.
Clinical results of the application of perftoran for the treatment of odontogenous abcesses and phlegmons in the maxillofacial region.
Durnovo EA, Furman IV, Pushkin SY, Maslennikov IA, Bondar OG, Ivanitsky GR.
Nizhny Novgorod State Medical Academy, Russia.
Abstract
INTRODUCTION: The study was carried out to ascertain the effects of perftoran in the treatment of facial and Dupuytren's phlegmons with simultaneous estimation of the general reaction in humans.
MATERIAL AND METHODS: Seventy-six patients with facial or Dupuytren's phlegmons were divided into 2 groups, one with mild and the other with a severe course of the inflammatory process. Each group was subdivided into 2 subgroups: one control group with "traditional" treatment and one study group where the traditional treatment was supplemented with perftoran. Perftoran was given to both study groups (1-3 ml/kg body weight, single intravenous injection) immediately after surgery plus further daily local wound treatment with perftoran until the end of exudation. The condition of the purulent wound and its reparative processes, the state of free-radical oxidation processes, antihypoxia and effects of perftoran were evaluated at various treatment stages (the moment of surgically opening the phlegmon, on the 1st, 3rd and 7th postoperative days).
RESULTS: Perftoran considerably decreased the tissue hypoxia as well as the transaminase and creatinine levels in blood serum. Perftoran helped to decrease the intoxication indices, hypoxaemia by 10-15%, to speed local wound healing by 2-5 days and to shorten the time of hospital treatment by 3-6 days on average.
CONCLUSIONS: The many positive effects of perftoran on the clinical course of the disease and on a series of homeostatic parameters allow us to recommend that this drug to be added for treating patients having odontogenous phlegmons in the maxillofacial region.
Сын ошибок трудных
Backyard Madness Champion!
Линейный вид
